SCHEMBL4066100

SCHEMBL4066100

CC(=O)Nc1cccc(-c2cc3ncnc(NCCc4c(C)[nH]c5c(F)ccc(C)c45)c3s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 2/20 0.49
MAP3K8 P41279 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPR1 P16066 1/20 0.38
FLT1 P17948 4/20 0.38
EGFR P00533 2/20 0.38
AURKA O14965 5/20 0.37
AURKB Q96GD4 4/20 0.37
NTRK1 P04629 4/20 0.37
RAF1 P04049 1/20 0.37
CSF1R P07333 1/20 0.37
AXL P30530 1/20 0.37
FLT4 P35916 1/20 0.37
NTRK2 Q16620 1/20 0.37
DDR2 Q16832 1/20 0.37
BRAF P15056 1/20 0.37
KDR P35968 1/20 0.37
TYK2 P29597 1/20 0.36
NQO2 P16083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3928997 0.89 CYP1A2 (0.42) NPC1RAB9AFLT1EGFRRAF1
SCHEMBL4071195 0.88 FLT1 (0.46) STK17BMAP3K8NPC1RAB9AFLT1
SCHEMBL4069302 0.88 NPC1 (0.44) STK17BNPC1RAB9AFLT1EGFR
SCHEMBL3930923 0.88 NPC1 (0.42) MAP3K8NPC1RAB9AFLT1EGFR
SCHEMBL4072674 0.87 STK17B (0.44) STK17BMAP3K8NPC1RAB9AFLT1
SCHEMBL3930445 0.87 FLT1 (0.43) STK17BMAP3K8NPC1RAB9AFLT1
SCHEMBL4065656 0.87 FLT1 (0.45) STK17BNPC1RAB9AFLT1EGFR
SCHEMBL4069259 0.87 USP2 (0.36) STK17BMAP3K8NPC1RAB9ANPR1
SCHEMBL3929417 0.86 STK17B (0.51) STK17BMAP3K8NPC1RAB9ANPR1
SCHEMBL3938262 0.86 IKBKB (0.42) STK17BMAP3K8NPC1RAB9AFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 STK17B 3100/4885MAP3K8 1818/4885NPC1 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.